Results 181 to 190 of about 194,004 (300)
Liquid Biopsy for Early Pancreatic Cancer Detection: Why Has It Not Yet Worked? [PDF]
Takahashi K +6 more
europepmc +1 more source
This study identifies vacuole membrane protein 1 (VMP1) as a critical regulator of intestinal epithelial barrier homeostasis. VMP1 facilitates the recruitment of CORO1C to late endosomes, supporting Retromer‐mediated recycling of the tight junction protein Occludin.
Jiawei Zhao +12 more
wiley +1 more source
From concept to clinic: emerging paradigms and novel insights into liquid biopsy. [PDF]
Guo W +7 more
europepmc +1 more source
ABSTRACT Extracellular vesicles (EVs) are nanoscale mediators of intercellular communication with diverse molecular cargoes that reflect their cell of origin. Advances in isolation, detection, and single‐particle analytics have revealed increasing molecular and functional heterogeneity, while exposing limitations in how EV identity and activity are ...
David J. Lundy +8 more
wiley +1 more source
The FAK‐STAT3‐NNMT axis drives anoikis resistance in circulating tumor cells by reprogramming fatty acid oxidation. Targeting this metabolic vulnerability suppresses metastasis, untangling a key mechanism of breast cancer progression and revealing NNMT as a promising therapeutic target.
Qingchao Tong +13 more
wiley +1 more source
Exosome crown proteins are promising markers for liquid biopsy of breast cancer. [PDF]
Tamkovich S +3 more
europepmc +1 more source
An implantable hydrogel is designed to hold gene transfection agents engineered to turn early recurrent tumor cells into generators of synthetic EVs. These synthetic EVs can express engineered miR‐26a (E‐miR‐26a) for highly sensitive detection and PD‐1 (a PD‐L1‐blocking agent) for therapeutic intervention, thereby enabling early detection and ...
Junli Zhang +7 more
wiley +1 more source
Molecular and immune biomarker testing in squamous-cell lung cancer: Effect of current and future therapies and technologies [PDF]
Bradley, Jeffrey D, et al,
core +1 more source
CRISPR/Cas13a: Compensatory Target Activation Mechanism
CRISPR/Cas13a‐CTAM as a novel compensatory target activation mechanism that enables synergistic activation of Cas13a via two independently editable short RNA effectors. This dual‐effector system maintains enzymatic activity comparable to traditional single‐effector while significantly enhancing flexibility, sensitivity, and application scope.
Bowen Jiang +8 more
wiley +1 more source

